TERN Terns Pharmaceuticals, Inc.
Price Chart
Executive Summary
Terns Pharmaceuticals announced that the FDA granted Breakthrough Therapy Designation (BTD) to its drug candidate TERN-701 for the treatment of chronic myeloid leukemia (Ph+ CML) in patients previously treated with two or more tyrosine kinase inhibitors. The designation, based on promising Phase 1/2 trial data showing strong molecular responses and a favorable safety profile, accelerates development and supports potential best-in-disease positioning. The filing also references an agreement for Merck to acquire Terns, signaling strong strategic validation.
Actionable Insight
The combination of FDA Breakthrough Therapy Designation and a pending acquisition by Merck represents a major validation of TERN-701's clinical and commercial potential. Traders should anticipate upward pressure on the stock price as the market prices in the increased likelihood of approval and a near-term acquisition close. Monitor for official merger proxy (DEFM14A) filing and any updates on the CARDINAL trial's progression to pivotal stage.
Key Facts
- FDA granted Breakthrough Therapy Designation to TERN-701 for Ph+ CML in chronic phase without T315I mutation in patients previously treated with two or more TKIs.
- BTD is based on Phase 1/2 CARDINAL trial data showing encouraging major and deep molecular responses at week 24, including in high-disease-burden patients.
- Most treatment-emergent adverse events were low-grade, with low rates of severe events and discontinuations.
- The press release explicitly states that the BTD, 'along with the recent agreement for Merck to acquire Terns,' has the potential to accelerate pivotal trial efforts.
- TERN-701 is a novel, oral, allosteric BCR::ABL1 inhibitor with potential best-in-disease profile.
Financial Impact
Significant positive impact due to FDA BTD and pending acquisition by Merck. BTD de-risks development and accelerates path to approval, increasing the probability of commercial success. The Merck deal implies substantial valuation upside, likely at a significant premium to current market cap ($6.1B).
Risk Factors
- Clinical trial results may not be replicated in larger, later-stage studies.
- The Merck acquisition could face regulatory scrutiny or fail to close.
- Forward-looking statements are subject to significant risks and uncertainties, including development timelines and safety profile.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179062 |
| Document: d122087dex991.htm | 0001193125-26-179062 |
| Document: 0001193125-26-179062-index-headers.html | 0001193125-26-179062 |
| Document: 0001193125-26-179062-index.html | 0001193125-26-179062 |
| Document: 0001193125-26-179062.txt | 0001193125-26-179062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
15-12G
| $52.97 awaiting T+1 | awaiting T+1 | — | — |
|
May 8, 2026
4w ago
|
EFFECT
| $52.95 $52.95 | · 0.00% | ▼ −0.23% | — |
|
May 5, 2026
5w ago
|
8-K
| $52.95 $52.95 | · 0.00% | ▼ −1.38% | — |
|
May 5, 2026
5w ago
|
25-NSE
| $52.95 $52.95 | · 0.00% | ▲ +1.38% | — |
|
Apr 27, 2026
6w ago
|
8-K
| $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
|
Apr 27, 2026
6w ago
|
Press Release
| $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
|
Mar 25, 2026
10w ago
|
Press Release
| $52.86 $53.17 | ▲ +0.59% | ▲ +2.36% | — |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $42.03 $41.51 | ▼ −1.24% | ▼ −0.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access